Zydus receives final approval from the USFDA for Plerixafor Injection USP, 24 mg/1.2 mL (20 mg/mL), Single-Dose Vial

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") has received final approval from the United States Food and Drug Administration (USFDA) for Plerixafor Injection, 24 mg/1.2 mL (20 mg/mL), Single-Dose Vial (USRLD: Mozobil® Injection, 24 mg/1.2 mL [20 mg/mL]).

Plerixafor is used by patients with certain types of cancer (non-Hodgkin's lymphoma-NHL, multiple myeloma-MM) to prepare them for stem cell transplant. The drug will be manufactured at the group's injectable manufacturing facility of Zydus Lifesciences Ltd. (Alidac) at SEZ, Ahmedabad (India).

Plerixafor Injection, 24 mg/1.2 mL (20 mg/mL), Single-Dose Vial had annual sales of USD 210 mn in the United States (IQVIA MAT May 2023).

The group now has 374 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.

(*as of 31st March 2023)

Shares of Zydus LifesciencesLimited was last trading in BSE at Rs. 649.80 as compared to the previous close of Rs. 622.45. The total number of shares traded during the day was 94615 in over 4595 trades.

The stock hit an intraday high of Rs. 656.50 and intraday low of 623.40. The net turnover during the day was Rs. 61138323.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 USFDA FinalApproval PlerixaforInjection